Lay off in CV for jardiance

AG takes over? WTF are you talking about. At its peak, it may get 5% share. And that share is at the expense of Farxiga.

if you’re letting the AG win in your territory, you should be 1st to go. Replace with a displaced respiratory or biosimilar rep.
If you don’t think they will be getting on formularies in 2025 you should be the 1st to go.
 




Unfortunately the integrated healthcare markets that we are all in love the word "generic" especially when multiple branded drugs are used in a disease state. AZ is doing the old "bait and switch" telling physicians to prescribe Farxiga over Jardiance because the patient "might" be able to get the approved generic dapa and "might" be able to save alot of money. The AZ reps know that the AG won't be covered and the pharmacist will then automatically give them brand Farxiga because in most cases it has as good of coverage as Jardiance in the Medicare D space.
 




Unfortunately the integrated healthcare markets that we are all in love the word "generic" especially when multiple branded drugs are used in a disease state. AZ is doing the old "bait and switch" telling physicians to prescribe Farxiga over Jardiance because the patient "might" be able to get the approved generic dapa and "might" be able to save alot of money. The AZ reps know that the AG won't be covered and the pharmacist will then automatically give them brand Farxiga because in most cases it has as good of coverage as Jardiance in the Medicare D space.
Next year the AG will be on formulary
 












































Known fact medicare plans do not announce their 2025 formularies until open enrollment in October.

usually 10/15 is the announcement. Some share changes with manufacturer before that.

regardless, the likelihood of a Medicare plan (or any plan for that matter) is very small. No rebates with the AG, and payors live off the rebate $$$.

if ‘price’ was a factor, Steglatro would be the market leader. They have a lower WAC price than the other SGLT2i’s.
 




usually 10/15 is the announcement. Some share changes with manufacturer before that.

regardless, the likelihood of a Medicare plan (or any plan for that matter) is very small. No rebates with the AG, and payors live off the rebate $$$.

if ‘price’ was a factor, Steglatro would be the market leader. They have a lower WAC price than the other SGLT2i’s.[/QUOTE

We hope you are correct, but we are not as sure about it as you. AZ has a plan for it.
 




usually 10/15 is the announcement. Some share changes with manufacturer before that.

regardless, the likelihood of a Medicare plan (or any plan for that matter) is very small. No rebates with the AG, and payors live off the rebate $$$.

if ‘price’ was a factor, Steglatro would be the market leader. They have a lower WAC price than the other SGLT2i’s.
The AG has more Rx than Steglatro since it launched. The AG continues to grow even without MC coverage. You are in denial.